View in EDS HTML Full Text PDF Full Text

Commentary on Foot et al.: Clinical considerations in addressing comorbid stimulant use in opioid use disorder.

Saved in:
Bibliographic Details
Title: Commentary on Foot et al.: Clinical considerations in addressing comorbid stimulant use in opioid use disorder.
Authors: Shulman, Matisyahu, Greiner, Miranda, Bisaga, Adam
Source: Addiction. Jan2024, Vol. 119 Issue 1, p158-159. 2p.
Subjects: Controlled release drugs, Naltrexone, Substance abuse, Central nervous system stimulants, Narcotic antagonists, Buprenorphine, Disease relapse, Risk assessment, Methamphetamine, Amphetamines, Cocaine, Drugs of abuse, Disease risk factors
Abstract: The authors comment on a secondary analysis by C. Foot et al on clinical considerations in addressing comorbid stimulant use in opioid use disorder. Topics include effective medications approved by the U.S. Food and Drug Administration (FDA) for the treatment of opioid use disorder, evidence for the use of a prescription stimulant in extended-release formulation to treat methamphetamine use disorder, and the need for further research to guide clinicians in the treatment of high-risk population.
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 174292878
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Commentary on Foot et al.: Clinical considerations in addressing comorbid stimulant use in opioid use disorder.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Shulman%2C+Matisyahu%22">Shulman, Matisyahu</searchLink><br /><searchLink fieldCode="AR" term="%22Greiner%2C+Miranda%22">Greiner, Miranda</searchLink><br /><searchLink fieldCode="AR" term="%22Bisaga%2C+Adam%22">Bisaga, Adam</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Addiction%22">Addiction</searchLink>. Jan2024, Vol. 119 Issue 1, p158-159. 2p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Controlled+release+drugs%22">Controlled release drugs</searchLink><br /><searchLink fieldCode="DE" term="%22Naltrexone%22">Naltrexone</searchLink><br /><searchLink fieldCode="DE" term="%22Substance+abuse%22">Substance abuse</searchLink><br /><searchLink fieldCode="DE" term="%22Central+nervous+system+stimulants%22">Central nervous system stimulants</searchLink><br /><searchLink fieldCode="DE" term="%22Narcotic+antagonists%22">Narcotic antagonists</searchLink><br /><searchLink fieldCode="DE" term="%22Buprenorphine%22">Buprenorphine</searchLink><br /><searchLink fieldCode="DE" term="%22Disease+relapse%22">Disease relapse</searchLink><br /><searchLink fieldCode="DE" term="%22Risk+assessment%22">Risk assessment</searchLink><br /><searchLink fieldCode="DE" term="%22Methamphetamine%22">Methamphetamine</searchLink><br /><searchLink fieldCode="DE" term="%22Amphetamines%22">Amphetamines</searchLink><br /><searchLink fieldCode="DE" term="%22Cocaine%22">Cocaine</searchLink><br /><searchLink fieldCode="DE" term="%22Drugs+of+abuse%22">Drugs of abuse</searchLink><br /><searchLink fieldCode="DE" term="%22Disease+risk+factors%22">Disease risk factors</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: The authors comment on a secondary analysis by C. Foot et al on clinical considerations in addressing comorbid stimulant use in opioid use disorder. Topics include effective medications approved by the U.S. Food and Drug Administration (FDA) for the treatment of opioid use disorder, evidence for the use of a prescription stimulant in extended-release formulation to treat methamphetamine use disorder, and the need for further research to guide clinicians in the treatment of high-risk population.
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=174292878
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/add.16374
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 2
        StartPage: 158
    Subjects:
      – SubjectFull: Controlled release drugs
        Type: general
      – SubjectFull: Naltrexone
        Type: general
      – SubjectFull: Substance abuse
        Type: general
      – SubjectFull: Central nervous system stimulants
        Type: general
      – SubjectFull: Narcotic antagonists
        Type: general
      – SubjectFull: Buprenorphine
        Type: general
      – SubjectFull: Disease relapse
        Type: general
      – SubjectFull: Risk assessment
        Type: general
      – SubjectFull: Methamphetamine
        Type: general
      – SubjectFull: Amphetamines
        Type: general
      – SubjectFull: Cocaine
        Type: general
      – SubjectFull: Drugs of abuse
        Type: general
      – SubjectFull: Disease risk factors
        Type: general
    Titles:
      – TitleFull: Commentary on Foot et al.: Clinical considerations in addressing comorbid stimulant use in opioid use disorder.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Shulman, Matisyahu
      – PersonEntity:
          Name:
            NameFull: Greiner, Miranda
      – PersonEntity:
          Name:
            NameFull: Bisaga, Adam
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: Jan2024
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-print
              Value: 09652140
          Numbering:
            – Type: volume
              Value: 119
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Addiction
              Type: main
ResultId 1